JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.13 -0.24

Buy Sell

Overview

Share price change

24h

Current

Min

3.98

Max

4.2

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+256.07% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	24M 252M
Previous open	4.37
Previous close	4.13

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 kwi 2026, 00:00 UTC

Major News Events

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 kwi 2026, 23:33 UTC

Earnings

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 kwi 2026, 22:40 UTC

Earnings

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:11 UTC

Earnings

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 kwi 2026, 21:01 UTC

Earnings

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 kwi 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 kwi 2026, 23:16 UTC

Earnings

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 kwi 2026, 23:15 UTC

Earnings

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 kwi 2026, 22:52 UTC

Earnings

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 kwi 2026, 22:51 UTC

Earnings

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 kwi 2026, 22:30 UTC

Earnings

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 kwi 2026, 22:30 UTC

Earnings

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 kwi 2026, 22:29 UTC

Earnings

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 kwi 2026, 22:27 UTC

Earnings

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 kwi 2026, 22:06 UTC

Market Talk

Earnings

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:47 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:37 UTC

Earnings

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 kwi 2026, 21:34 UTC

Earnings

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 kwi 2026, 21:29 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:20 UTC

Market Talk

Earnings

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

256.07% upside

12 Months Forecast

Average 14.67 USD 256.07%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.